PDCD1 and rhabdomyosarcoma: This is the case of the longest progression-free survival for PD-1 inhibitors on Rhabdomyosarcoma, which supported that positive PD-L1, TMB-H, and MSI-H could be strong beneficial biomarkers for immunotherapy in Rhabdomyosarcoma.